RecruitingNCT06690970
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Sponsor
Tianjin Medical University
Enrollment
500 participants
Start Date
Sep 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria1
- \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria1
- \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interventions
DIAGNOSTIC_TEST68Ga/18F-PSMA/PSFA
Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06690970
Related Trials
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT057519412 locations